A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team

C. Fleming, J. H. Wasson, P. C. Albertsen, M. J. Barry and J. E. Wennberg
Biomedical Information Communications Center, Oregon Health Sciences University, Portland.

OBJECTIVE--To model the impact of initial therapy on outcomes for men with localized (clinical stage A or B) prostatic carcinoma. DESIGN--A decision analysis modeling three strategies: radical prostatectomy, external-beam radiation therapy, and watchful waiting, with delayed hormonal therapy if metastatic disease develops. We modeled the main benefit of treatment as a reduction in the chance of death or disutility from metastatic disease. These benefits were offset in the model by the risks of treatment-related morbidity and mortality. The model was used to analyze expected outcomes by tumor grade (well, moderately, and poorly differentiated) for men 60 to 75 years of age. DATA--Probabilities and rates for important clinical events, obtained through review of the literature for prostatic carcinoma and analysis of Medicare claims data. MAIN RESULTS--Several patterns emerged within the range of uncertainty about the risks and benefits of treatment for prostatic carcinoma. In patients with well-differentiated tumor grades, based on clinical staging, treatment at best offers limited benefit in terms of quality-adjusted life expectancy and may result in harm to the patient. Among patients with moderately or poorly differentiated tumors, if we use the most optimistic assumptions about treatment efficacy, then patients aged 60 to 65 years would benefit from either radical prostatectomy or external-beam radiation therapy, compared with watchful waiting. However, in most other cases, treatment offers less than a 1-year improvement in quality-adjusted life expectancy or decreases the quality-adjusted life expectancy compared with watchful waiting. Invasive treatment generally appears to be harmful for patients older than 70 years. CONCLUSIONS--Radical prostatectomy and radiation therapy may benefit selected groups of patients with localized prostate cancer, particularly younger patients with higher-grade tumors. However, our model shows that in most cases the potential benefits of therapy are small enough that the choice of therapy is sensitive to the patient's preferences for various outcomes and discounting. The choice of watchful waiting is a reasonable alternative to invasive treatment for many men with localized prostatic carcinoma.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era
Shimizu et al.
Jpn J Clin Oncol 2007;0:hym105v1-12.
ABSTRACT | FULL TEXT  

Histological Diagnosis of Prostate Cancer in Korean Men Aged 70 79 Years
Shim et al.
Jpn J Clin Oncol 2007;0:hym093v1-6.
ABSTRACT | FULL TEXT  

Is Proton Beam Therapy Cost Effective in the Treatment of Adenocarcinoma of the Prostate?
Konski et al.
JCO 2007;25:3603-3608.
ABSTRACT | FULL TEXT  

A Review and Meta-Analysis of Prostate Cancer Utilities
Bremner et al.
Med Decis Making 2007;27:288-298.
ABSTRACT  

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller et al.
JNCI J Natl Cancer Inst 2006;98:1134-1141.
ABSTRACT | FULL TEXT  

The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:1485-1489.
ABSTRACT | FULL TEXT  

Being there is important, but getting there matters too: the role of path in the valuation process.
Goldberg
Med Decis Making 2006;26:323-337.
ABSTRACT  

Preference Assessment Method Affects Decision-Analytic Recommendations: A Prostate Cancer Treatment Example
Elkin et al.
Med Decis Making 2004;24:504-510.
ABSTRACT  

The Implications of Differing Methods of Utility Assessment for Patient-Specific Decision-Analytic Tools
Yi
Med Decis Making 2004;24:536-537.
 

Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000
McNaughton-Collins et al.
J Natl Cancer Inst Monogr 2004;2004:78-101.
ABSTRACT | FULL TEXT  

Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study
Potosky et al.
JNCI J Natl Cancer Inst 2004;96:1358-1367.
ABSTRACT | FULL TEXT  

Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group
Scher et al.
JCO 2004;22:537-556.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Screening in Elderly Men
Lu-Yao et al.
JNCI J Natl Cancer Inst 2003;95:1792-1797.
ABSTRACT | FULL TEXT  

Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?
Alibhai et al.
JCO 2003;21:3318-3327.
ABSTRACT | FULL TEXT  

Effectiveness of Interventions for Reducing the Frequency of Radical Prostatectomy Procedures in the Elderly: An Evaluation
Sheikh and Bullock
American Journal of Medical Quality 2003;18:97-103.
ABSTRACT  

Cost-utility analysis: Use QALYs only with great caution
McGregor
CMAJ 2003;168:433-434.
FULL TEXT  

Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris and Lohr
ANN INTERN MED 2002;137:917-929.
ABSTRACT | FULL TEXT  

Cancer Survival Among US Whites and Minorities: A SEER (Surveillance, Epidemiology, and End Results) Program Population-Based Study
Clegg et al.
Arch Intern Med 2002;162:1985-1993.
ABSTRACT | FULL TEXT  

A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer
Holmberg et al.
NEJM 2002;347:781-789.
ABSTRACT | FULL TEXT  

What Questions Do Families of Patients With Early-Stage Prostate Cancer Want Answered?
Feldman-Stewart et al.
Journal of Family Nursing 2001;7:188-207.
ABSTRACT  

Prostate Cancer: What Is the Future Role for Imaging?
Thornbury et al.
Am. J. Roentgenol. 2001;176:17-22.
FULL TEXT  

Cost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer
Bayoumi et al.
JNCI J Natl Cancer Inst 2000;92:1731-1739.
ABSTRACT | FULL TEXT  

Prostate Cancer Staging: Should MR Imaging Be Used?-A Decision Analytic Approach
Jager et al.
Radiology 2000;215:445-451.
ABSTRACT | FULL TEXT  

The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:977-983.
ABSTRACT | FULL TEXT  

The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:987-992.
ABSTRACT | FULL TEXT  

What Questions Do Patients with Curable Prostate Cancer Want Answered?
Feldman-Stewart et al.
Med Decis Making 2000;20:7-19.
ABSTRACT  

Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study
Potosky et al.
JNCI J Natl Cancer Inst 1999;91:1719-1724.
FULL TEXT  

Prostate Cancer Tumor Grade Differentiation with Dynamic Contrast-enhanced MR Imaging in the Rat: Comparison of Macromolecular and Small-Molecular Contrast Media-Preliminary Experience
Gossmann et al.
Radiology 1999;213:265-272.
ABSTRACT | FULL TEXT  

Improving Appropriate Selection of Radical Prostatectomy for Prostate Cancer
Lewis and Rising
Eval Health Prof 1998;21:429-441.
ABSTRACT  

The Danger of Applying Group-level Utilities in Decision Analyses of the Treatment of Localized Prostate Cancer in Individual Patients
Cowen et al.
Med Decis Making 1998;18:376-380.
ABSTRACT  

Gains in Life Expectancy from Medical Interventions -- Standardizing Data on Outcomes
Wright and Weinstein
NEJM 1998;339:380-386.
ABSTRACT | FULL TEXT  

Prostate Cancer Patients' Utilities for Health States: How It Looks Depends on Where You Stand
Chapman et al.
Med Decis Making 1998;18:278-286.
ABSTRACT  

Dollars May Not Buy as Many QALYs as We Think:: A Problem with Defining Quality-of-life Adjustments
Fryback and Lawrence
Med Decis Making 1997;17:276-284.
ABSTRACT  

Discussion of the controversies associated with prostate cancer screening
Wolfe and Wolfe
The Journal of the Royal Society for the Promotion of Health 1997;117:151-155.
ABSTRACT  

Trends in Radical Prostatectomy in New York State
Imperato et al.
American Journal of Medical Quality 1996;11:205-213.
ABSTRACT  

The role of motility proteins and metastasis-suppressor genes in prostate cancer progression
Rinker-Schaeffer et al.
Stem Cells 1996;14:508-516.
ABSTRACT  

Screening for Prostate Cancer
Catalona et al.
NEJM 1996;334:666-668.
FULL TEXT  

Screening for Prostate Cancer with Prostate-Specific Antigen -- An Examination of the Evidence
Woolf
NEJM 1995;333:1401-1405.
FULL TEXT  

Management of Cancer of the Prostate
Catalona
NEJM 1994;331:996-1004.
FULL TEXT  

Conservative Management of Prostate Cancer
Catalona et al.
NEJM 1994;330:1830-1832.
FULL TEXT  

Preventive Health Services in Adults
Sox
NEJM 1994;330:1589-1595.
FULL TEXT  

Results of Conservative Management of Clinically Localized Prostate Cancer
Chodak et al.
NEJM 1994;330:242-248.
ABSTRACT | FULL TEXT  

Radical Prostatectomy Is on the Rise, Despite Questions about Its Value
Journal Watch Dermatology 1993;1993:17-17.
FULL TEXT  

RADICAL PROSTATECTOMY IS INCREASING, DESPITE QUESTIONS ABOUT ITS VALUE
JWatch General 1993;1993:1-1.
FULL TEXT